P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA
S. Vallone,F. Passiglia,A. Listi,P. Bironzo,A. Merlini, F. Benso,F. Napoli, F. A. Barbu,V. Zambelli,F. Tabbo,M. L. Reale,C. Sini,E. Roca, P. A. Taveggia, F. Simionato,L. Buffoni,L. Mazilu,V. Barbieri,D. Pignataro,A. Araujo,L. Paz-Ares,E. Felip, N. Secen,A. Comanescu, K. Mati Ramizi, A. C. Bettini,V. Scotti,H. Linardou,K. Mohorcic,G. Meoni,M. Volante,G. Scagliotti,U. Malapelle,L. Righi,S. Novello JOURNAL OF THORACIC ONCOLOGY（2024）
关键词
Precision medicine,lung cancer,molecular biomarkers
AI 理解论文
溯源树
样例
